Lates News

According to Every AI Express, Dongwu Securities released a research report on August 17th, giving a buy rating to Xinnoway (300765.SZ). The rating reasons mainly include: 1) a slight increase in H1 revenue and a significant decline in profits; 2) EGFR ADC first readout data at the AACR conference, with potential "blockbuster bomb" drugs; 3) the company continues to increase research and development, with a comprehensive layout of ADC, mRNA, and monoclonal antibody drugs. (Daily Economic News)